

In the Claims:

1-118. (Canceled).

119. (Currently amended) An isolated nucleic acid having at least 80% nucleic acid sequence identity to:

- (a) ~~a nucleic acid sequence encoding the polypeptide shown in Figure 252 (SEQ ID NO:357);~~
- (b) ~~a nucleic acid sequence encoding the polypeptide shown in Figure 252 (SEQ ID NO:357), lacking its associated signal peptide;~~
- (c) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 252 (SEQ ID NO:357);~~
- (d) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 252 (SEQ ID NO:357), lacking its associated signal peptide;~~
- (e) the nucleic acid sequence of SEQ ID NO:356 shown in Figure 251 (SEQ ID NO:356);
- ~~(f)~~(d) the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:356 shown in Figure 251 (SEQ ID NO:356); or
- ~~(g)~~(e) the full-length coding sequence of the cDNA deposited under ATCC accession number 203088;
wherein, said nucleic acid is amplified in lung adenocarcinomas.

120. (Currently amended) An isolated nucleic acid having at least 85% nucleic acid sequence identity to:

- (a) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:357 ~~shown in Figure 252 (SEQ ID NO:357);~~
- (b) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:357 ~~shown in Figure 252 (SEQ ID NO:357), lacking its associated signal peptide;~~
- (c) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 252 (SEQ ID NO:357);~~
- (d) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 252 (SEQ ID NO:357), lacking its associated signal peptide;~~
- (e) the nucleic acid sequence of SEQ ID NO:356 ~~shown in Figure 251 (SEQ ID NO:356);~~

~~(f)~~(d) the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:356 shown in Figure 251 (SEQ ID NO:356); or

~~(g)~~(e) the full-length coding sequence of the cDNA deposited under ATCC accession number 203088;

wherein, said nucleic acid is amplified in lung adenocarcinomas.

121. (Currently amended) An isolated nucleic acid having at least 90% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:357 shown in Figure 252 (SEQ ID NO:357);

(b) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:357 shown in Figure 252 (SEQ ID NO:357), lacking its associated signal peptide;

~~(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 252 (SEQ ID NO:357);~~

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 252 (SEQ ID NO:357), lacking its associated signal peptide;~~

~~(e) the nucleic acid sequence of SEQ ID NO:356 shown in Figure 251 (SEQ ID NO:356);~~

~~(f)~~(d) the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:356 shown in Figure 251 (SEQ ID NO:356); or

~~(g)~~(e) the full-length coding sequence of the cDNA deposited under ATCC accession number 203088;

wherein, said nucleic acid is amplified in lung adenocarcinomas.

122. (Currently amended) An isolated nucleic acid having at least 95% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:357 shown in Figure 252 (SEQ ID NO:357);

(b) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:357 shown in Figure 252 (SEQ ID NO:357), lacking its associated signal peptide;

- (c) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 252 (SEQ ID NO:357);~~
- (d) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 252 (SEQ ID NO:357), lacking its associated signal peptide;~~
- (e) the nucleic acid sequence of SEQ ID NO:356 shown in Figure 251 (SEQ ID NO:356);
- (f)(d) the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:356 shown in Figure 251 (SEQ ID NO:356); or
- (g)(e) the full-length coding sequence of the cDNA deposited under ATCC accession number 203088;
wherein, said nucleic acid is amplified in lung adenocarcinomas.

123. (Currently amended) An isolated nucleic acid having at least 99% nucleic acid sequence identity to:

- (a) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:357 shown in Figure 252 (SEQ ID NO:357);
- (b) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:357 shown in Figure 252 (SEQ ID NO:357), lacking its associated signal peptide;
- (c) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 252 (SEQ ID NO:357);~~
- (d) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 252 (SEQ ID NO:357), lacking its associated signal peptide;~~
- (e) the nucleic acid sequence of SEQ ID NO:356 shown in Figure 251 (SEQ ID NO:356);
- (f)(d) the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:356 shown in Figure 251 (SEQ ID NO:356); or
- (g)(e) the full-length coding sequence of the cDNA deposited under ATCC accession number 203088;
wherein, said nucleic acid is amplified in lung adenocarcinomas.

124. (Currently amended) An isolated nucleic acid comprising:

- (a) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:357 ~~shown in Figure 252 (SEQ ID NO:357);~~
- (b) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:357 ~~shown in Figure 252 (SEQ ID NO:357),~~ lacking its associated signal peptide;
- (c) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 252 (SEQ ID NO:357);~~
- (d) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 252 (SEQ ID NO:357),~~ lacking its associated signal peptide;
- (e) the nucleic acid sequence of SEQ ID NO:356 ~~shown in Figure 251 (SEQ ID NO:356);~~
- (f)(d) the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:356 ~~shown in Figure 251 (SEQ ID NO:356);~~ or
- (g)(e) the full-length coding sequence of the cDNA deposited under ATCC accession number 203088.

125. (Currently amended) The isolated nucleic acid of Claim 124 comprising a nucleic acid sequence encoding the polypeptide of SEQ ID NO:357 ~~shown in Figure 252 (SEQ ID NO:357).~~

126. (Currently amended) The isolated nucleic acid of Claim 124 comprising a nucleic acid sequence encoding the polypeptide of SEQ ID NO:357 ~~shown in Figure 252 (SEQ ID NO:357),~~ lacking its associated signal peptide.

127-128. Canceled.

129. (Currently amended) The isolated nucleic acid of Claim 124 comprising the nucleic acid sequence of SEQ ID NO:356 ~~shown in Figure 251 (SEQ ID NO:356).~~

130. (Currently amended) The isolated nucleic acid of Claim 124 comprising the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:356 ~~shown in Figure 251 (SEQ ID NO:356).~~

131. (Previously presented) The isolated nucleic acid of Claim 124 comprising the full-length coding sequence of the cDNA deposited under ATCC accession number 203088.
- 132-134. Canceled.
135. (Currently amended) A vector comprising the nucleic acid of Claim 124 ~~119~~.
136. (Previously presented) The vector of Claim 135, wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.
137. (Previously presented) A host cell comprising the vector of Claim 135.
138. (Previously presented) The host cell of Claim 137, wherein said cell is a CHO cell, an *E. coli* or a yeast cell.
139. (New) An isolated nucleic acid molecule at least 20 nucleotides in length that hybridizes under stringent conditions to:
- (a) the nucleic acid sequence of SEQ ID NO: 356 or a complement thereof; or
 - (b) the full-length coding sequence of the cDNA deposited under ATCC accession number 203088 or a complement thereof;
- wherein, said stringent conditions use 50% formamide, 5X SSC, 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5X Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, and washes at 42°C in 0.2X SSC, at 55°C in 50% formamide followed by a high-stringency wash at 55°C in 0.1X SSC, EDTA; and wherein said isolated nucleic acid molecule is suitable for use as a PCR primer or probe.
140. (New) The isolated nucleic acid molecule of Claim 139 that is at least 50 nucleotides or above in length.

- 141. (New) The isolated nucleic acid molecule of Claim 139 that is at least 60 nucleotides or above in length.
- 142. (New) The isolated nucleic acid molecule of Claim 139 that is at least 70 nucleotides or above in length.
- 143. (New) The isolated nucleic acid molecule of Claim 139 that is at least 80 nucleotides or above in length.
- 144. (New) The isolated nucleic acid molecule of Claim 139 that is at least 90 nucleotides or above in length.
- 145. (New) The isolated nucleic acid molecule of Claim 139 that is at least 100 nucleotides or above in length.